Halozyme Therapeutics (NASDAQ:HALO) Rating Reiterated by JMP Securities : vimarsana.com

Halozyme Therapeutics (NASDAQ:HALO – Get Free Report)‘s stock had its “market outperform” rating reaffirmed by investment analysts at JMP Securities in a note issued to investors on Thursday, Benzinga reports. They presently have a $72.00 price objective on the biopharmaceutical company’s stock. JMP Securities’ price target would indicate a potential upside of 108.82% from the […]

Related Keywords

Ireland , United States , Japan , Belgium , Switzerland , Michaelj Labarre , , Vanguard Group Inc , Artisan Partners Limited Partnership , Halozyme Therapeutics Inc , Morgan Stanley , Halozyme Therapeutics Company Profile , Macquarie Group Ltd , Goldman Sachs Group , Geode Capital Management , Halozyme Therapeutics , Get Free Report , Therapeutics Stock Down , Partners Limited Partnership , Capital Management , Halozyme Therapeutics Daily , Nasdaq Halo , Halo , Medical , 40637h10 , Reiterated Rating , Jmp Securities ,